Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 163Endometrial Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 5Recurrence 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Intraductal, Noninfiltrating 4Triple Negative Breast Neoplasms 3Breast Diseases 3Breast Cancer Metastatic 3Prostatic Neoplasms 2Leiomyosarcoma 2Carcinoma, Lobular 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Polycystic Ovary Syndrome 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pain 1Osteoporosis 1Neoplastic Cells, Circulating 1Neoadjuvant Operable Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphangioleiomyomatosis 1

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone-sensitive Metastatic Breast Cancer × Letrozole × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡